Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK6 | Q00534 | 19/20 | 0.79 |
| ▸ | CDK4 | P11802 | 16/20 | 0.79 |
| ▸ | CDK1 | P06493 | 14/20 | 0.79 |
| ▸ | CCND3 | P30281 | 10/20 | 0.79 |
| ▸ | CDK2 | P24941 | 8/20 | 0.79 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.79 |
| ▸ | CDK7 | P50613 | 4/20 | 0.79 |
| ▸ | CDK9 | P50750 | 4/20 | 0.79 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.79 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.79 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.79 |
| ▸ | CCND1 | P24385 | 2/20 | 0.79 |
| ▸ | CIT | O14578 | 1/20 | 0.79 |
| ▸ | GAK | O14976 | 1/20 | 0.79 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.79 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.79 |
| ▸ | STK16 | O75716 | 1/20 | 0.79 |
| ▸ | CCNK | O75909 | 1/20 | 0.79 |
| ▸ | STK10 | O94804 | 1/20 | 0.79 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15252470 | 0.94 | CDK6 (0.88) | CDK6CDK4CDK1CCND3CDK2 | |
| SCHEMBL19057207 | 0.94 | CDK6 (0.90) | CDK6CDK4CDK1CCND3CDK2 | |
| SCHEMBL19220702 | 0.94 | CDK6 (0.79) | CDK6CDK4CDK1CCND3CDK2 | |
| SCHEMBL19209863 | 0.88 | CDK6 (0.70) | CDK6CDK4CDK1CCND3CDK2 | |
| Abemaciclib SCHEMBL29591527 | 0.88 | CDK4 (1.00) | CDK6CDK4CDK1CCND3CDK2 | |
| Abemaciclib SCHEMBL29356350 | 0.88 | CDK4 (1.00) | CDK6CDK4CDK1CCND3CDK2 | |
| SCHEMBL2487954 | 0.88 | CDK6 (0.88) | CDK6CDK4CDK1CCND3CDK2 | |
| Abemaciclib SCHEMBL29423472 | 0.88 | CDK4 (1.00) | CDK6CDK4CDK1CCND3CDK2 | |
| Abemaciclib SCHEMBL2487229 | 0.88 | CDK4 (1.00) | CDK6CDK4CDK1CCND3CDK2 | |
| SCHEMBL17488760 | 0.88 | CDK4 (0.88) | CDK6CDK4CDK1CCND3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | BTK, CDK6, CDK4 | CDK6 2/4885CDK4 3/4885CDK1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.